Transcript Highlights:

• to address gaps in the human performance projects and up to $14 million to address gaps in the pharmaceutical
• On page two, it looks like we have new funding, $14 million, to OSU on the Pharmaceutical Expansion Program
• Again, yeah, this was the pharmaceutical program that they've had in place, and this was just a funding

Bills: HB4028, HB4029, HB4059, HB4063, HB4073, HB4074, HB4075, HB4076, HB4077, HB4078, SB1130, SB1131, SB1132, SB1133, SB1134, SB1142

Keywords: tax deduction, venture capital, economic development, Oklahoma, investment, ALS, funding, healthcare, State Department of Health, emergency declaration, public finance, state budget, financial regulations, monetary policy, referendum, constitutional amendments, special election, Oklahoma legislature, public voting, recovery fund

Summary: The Joint Committee on Appropriations and Budget met and first took up House Bill 4063, adopting a committee substitute over objection by a 17-4 roll call vote. The bill, as explained by the Pro Tem, moves the election dates for House Bill 4440 and Joint Resolution 1024 to August 25, 2026. Members debated whether the measure violated the single-subject rule or was an attempt to revisit proposals that had previously failed, but the committee advanced it and it passed 16-6 after debate. The committee then considered a series of appropriations and reappropriations, largely involving ARPA and interest funds. These included Senate Bills 1130 through 1134 and 1142, which redirected funds to the University Hospital Authority and Trust, the Office of Juvenile Affairs, the State Department of Health for rural hospital rebuild efforts, the Department of Mental Health and Substance Abuse Services for Griffin Memorial Hospital capacity, and DHS-related projects including Boys & Girls Club and YWCA funding. All of these bills passed, with most receiving broad support and only a few dissenting votes. Members also advanced several House bills: HB 4029 appropriated funds to the State Department of Health and the ALS fund; HB 4074 gave the Health Care Workforce Training Commission flexibility to close out ARPA projects and transfer funds among nursing-related programs; HB 4075 reappropriated water and wastewater funds within OWRB; HB 476 provided rural economic impact grant funding for water, wastewater, sewer, air park, industrial park, and broadband-related projects; HB 477 funded emergency response and relief grants with standard administrative language; HB 478 covered ARPA closeout costs for consultants and the grants management office; HB 428 extended a qualified equity investment tax deduction sunset; and HB 473 and HB 4073 pulled back ARPA funds for reappropriation and closeout. Most measures passed on strong roll-call votes, and the committee adjourned after HB 4073 passed 21-0.

Transcript Highlights:

• appropriates money to OSUMA for the continuation of the human performance project and also their pharmaceutical

Bills: HB4028, HB4029, HB4059, HB4063, HB4073, HB4074, HB4075, HB4076, HB4077, HB4078, SB1130, SB1131, SB1132, SB1133, SB1134, SB1142

Keywords: tax deduction, venture capital, economic development, Oklahoma, investment, ALS, funding, healthcare, State Department of Health, emergency declaration, public finance, state budget, financial regulations, monetary policy, referendum, constitutional amendments, special election, Oklahoma legislature, public voting, recovery fund

Summary: The committee considered a series of bills largely focused on reappropriating and closing out ARPA-related funds, transferring interest earnings, and filling funding gaps in existing state projects. Measures included funding for the Health Care Workforce Training Commission, juvenile services in Rogers County, rural hospital rebuild projects, DHS-related projects for Boys and Girls Clubs and the YWCA, water and wastewater projects through the OWRB, ALS grant limits for OSDH, pandemic relief accounting, administrative costs for ARPA projects, pediatric cardiology and OSU-related projects, rural industrial park and port water/wastewater gaps, and emergency response grants through the Department of Emergency Management. Most of these bills were presented by Rep. Newton, Chairman Caldwell, Speaker Hilbert, Rep. Osborne, Rep. Hill, and others, with committee substitutes adopted without objection where noted. One bill, House Bill 4028, drew the most discussion. It would extend the sunset on the qualified equity investment deduction for venture capital investments. Members questioned the lack of program-specific evaluation data, including return on investment, jobs created, and how much of the tax deduction had actually been used. The sponsor said the program had helped grow Oklahoma venture capital and that he would seek better data, but argued the sunset should be extended for now. The bill passed 23-6. Another extended exchange centered on House Bill 4063, which combined measures related to placing state questions on the August ballot, including HJR 1024 and a bill tied to House Bill 1440. Members raised concerns about single-subject issues, ballot timing, voter turnout, and whether combining the measures limited legislators’ options. The Speaker defended the approach as election-related and noted prior precedent. The bill passed 23-6. The remaining bills were approved overwhelmingly, generally by votes of 27-0, 28-0, or 29-0, and were reported out with due pass recommendations before the meeting adjourned.

Transcript Highlights:

• I don't know if we'll touch on this, but pharmaceutical-grade xylazine versus non-pharmaceutical-grade
• compounds that you would attain from a pharmacy or from a pharmaceutical distributor or a compounding
• The non-PG, as we call non-pharmaceutical-grade compounds.
• compounds can easily go missing.
• Hogan, you called it a cousin compounds. Yeah, that's not proper. Compounds.

Keywords: 995, all

Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.

Transcript Highlights:

• So this problem compounds at every level.
• So that one part of that other comment I want to make about compounding too, not necessarily all compounding
• There are some... to make about compounding too, not necessarily all compounding is cheap.
• So it's not necessarily that compounding is always cheap. because now you're getting compounding, right
• And so, because the FDA hasn't approved compounding, payers can make a decision not to pay for compounded

Keywords: 1184, house, all

Transcript Highlights:

• You also have compounded drugs.
• pharmacies and compounded drugs.
• And with pharmaceuticals, any kind of health care, but especially with pharmaceuticals, which are so
• Now it's pharmaceuticals.
• And that's a combination of using a lot of pharmaceuticals and very, very expensive pharmaceuticals.

Transcript Highlights:

• oral medications, additionally minor surgical procedures and injections, and eventually all oral pharmaceutical

Bills: HB99, HJR5, HM39, HB206, HB213, SB41, SB153, SB165, SB261, SB264

Keywords: medical malpractice, malpractice reform, patient's compensation fund, PCF, health care liability, tort reform, damage caps, punitive damages, hospital liability, physician liability, nurse practitioner, certified nurse-midwife, outpatient facility, ambulatory surgical center, urgent care, free-standing emergency room, insurance surcharge, superintendent of insurance, New Mexico hospitals, medical review process

Transcript Highlights:

• oral medications, additionally minor surgical procedures and injections, and eventually all oral pharmaceutical
• oral medications, additionally minor surgical procedures and injections, and eventually all oral pharmaceutical
• Additionally, minor surgical procedures and injections, and eventually all oral pharmaceutical agents

Bills: HB99, HJR5, HM39, HB206, HB213, SB41, SB153, SB165, SB261, SB264

Keywords: medical malpractice, malpractice reform, patient's compensation fund, PCF, health care liability, tort reform, damage caps, punitive damages, hospital liability, physician liability, nurse practitioner, certified nurse-midwife, outpatient facility, ambulatory surgical center, urgent care, free-standing emergency room, insurance surcharge, superintendent of insurance, New Mexico hospitals, medical review process

Summary: The committee first took up House Bill 99, a medical malpractice reform measure. Sponsor Chair Chandler and Minority Leader Armstrong described months of stakeholder negotiations aimed at balancing patient compensation with concerns from physicians, hospitals, and insurers about litigation costs, punitive damages, and access to care. The committee substitute kept the existing monetary damage caps but changed several provisions, including definitions of “occurrence” and “value of medical care,” treatment of future medical expenses, a higher clear-and-convincing standard for punitive damages, a two-step process before punitive damages can be pled, and a lower punitive-damages cap for smaller providers versus a higher cap for large hospital systems. Supporters said the bill would help recruit and retain doctors and stabilize the malpractice market; opponents argued it weakens accountability, especially for corporate and out-of-state hospital systems, and several speakers urged a stronger amendment to preserve patient rights. After debate, the committee voted 10-0 to give the House Judiciary Committee substitute for HB 99 a do-pass recommendation. The committee then heard House Joint Resolution 5, which would amend the state constitution to allow legislative compensation. Sponsors and supporters said paying legislators would make service more accessible to working people, parents, rural residents, and others without independent wealth, and would broaden representation. Several advocacy groups and individual commenters backed the proposal, while members raised questions about the pay formula, with the resolution tying compensation to the state median income. Some members supported the idea but preferred a salary commission or a different mechanism. The committee approved HJR 5 on a 7-3 vote. Finally, the committee began hearing House Memorial 39, which calls for a task force to study the current state of sexual assault examination kits and report on backlog progress. Sponsor Rep. Ferrari and the New Mexico Coalition of Sexual Assault Programs explained that a prior task force a decade ago found more than 5,000 untested kits and led to policy changes, including the Sexual Assault Survivors Bill of Rights and a statewide tracking system. The memorial is intended to reassess whether backlogs remain and recommend further fixes.

Bills: HB99, HJR5, HM39, HB206, HB213, SB41, SB153, SB165, SB261, SB264

Keywords: medical malpractice, malpractice reform, patient's compensation fund, PCF, health care liability, tort reform, damage caps, punitive damages, hospital liability, physician liability, nurse practitioner, certified nurse-midwife, outpatient facility, ambulatory surgical center, urgent care, free-standing emergency room, insurance surcharge, superintendent of insurance, New Mexico hospitals, medical review process

Summary: The committee first took up a lengthy informational presentation on the Patient Compensation Fund (PCF) and New Mexico medical malpractice insurance. Teresa Hassey, a plaintiffs’ attorney, described the PCF’s origin in the 1976 Medical Malpractice Act, its role as a state-backed excess coverage system, and her view that it was mismanaged when hospital participation expanded without individualized risk assessments. She argued that hospitals underpaid surcharges, that the fund was depleted by claims, and that the 2021 amendments and later legislative infusions were meant to shore up deficits and phase hospitals out. Superintendent of Insurance Alice Kane and LFC analyst Julia Rodriguez presented a different perspective, emphasizing recent general fund infusions, current surcharge collections, the use of actuarial reviews, and the PCF’s budget and settlement activity. Kane said the market is highly concentrated, New Mexico’s malpractice costs and defense expenses are high, and the fund still provides lower-cost coverage than the open market, while also noting ongoing issues with future medical claims, TPA transition, and investment management. Committee members questioned the presenters at length about why New Mexico malpractice premiums are so high, whether defense costs were being conflated with claim payouts, how the PCF works with primary coverage and excess coverage, and whether hospitals were properly assessed when they entered the fund. Several senators raised concerns about punitive damages, corporate practice of medicine, and whether the state’s legal environment is driving doctors away. Others challenged the data comparisons, noting differences between one-year figures and multi-year averages, and asked why New Mexico’s costs remain far above neighboring states. Kane and Hassey disagreed on the causes, with Kane pointing to high claims and defense costs over time and Hassey arguing that hospital participation and punitive-damage exposure distorted the market. The chair concluded the discussion by saying the committee had not exhausted the topic and that he still wanted a clear path to reducing doctors’ insurance costs. After a break, the committee moved on to Senate Bill 41. Senator Charlie introduced the bill, which would eliminate the statute of limitations for the most serious sexual crimes in New Mexico. He argued that trauma, coercion, fear, and delayed disclosure often prevent survivors from reporting promptly, and said the law should reflect that reality. The bill was presented as a response to survivor testimony heard in a prior hearing, and the sponsor framed it as part of a broader effort to modernize the justice system for sexual violence cases.

Bills: SB437, SB528, SB626, SB636, SB884, SB968, SB1044, SB1608, SB2336

Keywords: healthcare, training, abuse, neglect, penalties, chemical dependency, safety, regulation, inpatient competency restoration, competency restoration, forensic mental health, mental health law, criminal competency, incompetent to stand trial, Chapter 46B, HHSC, Health and Human Services Commission, state hospital, behavioral health, local mental health authority

Transcript Highlights:

• that is not prescribed in any way, shape, or form, but coming completely when the issue that the pharmaceutical
• the doctors, the physicians, as well as nurse practitioners, as well as PAs, were going by the pharmaceutical
• The pharmaceutical companies were wrong. Correct.
• The information is super important because so many of our doctors and nurses, etc., rely on the pharmaceutical

Bills: HB35, HB4490, HB4454, HB2188, HB3078, HB4743, HB2556, HB46, HB5342, HB4783, HB3785, HB5278, HB1639, HB2581, HB4224, HB4070, HB4099, HB4882, HB3794, HB46

Keywords: peer support, first responders, mental health, confidentiality, emergency services, disclosure, next of kin, public information, deceased persons, privacy rights, patient solicitation, marketing practices, healthcare regulation, task force, deceptive advertising, nurse aide, certification, Texas Board of Nursing, healthcare workforce, nursing standards

Transcript Highlights:

• be compounded.
• Are you making the compound and doing it?
• That's my concern, as I am a firsthand user of compounding.
• The rules already require that compounding pharmacies...
• It's a pharmaceutical.

Bills: HB46, HB35, HB4490, HB4454, HB2188, HB3078, HB4743, HB2556, HB46, HB5342, HB4783, HB3785, HB5278, HB1639, HB2581, HB4224, HB4070, HB4099, HB4882, HB3794

Keywords: local government spending cap, expenditure limit, political subdivision, property tax, ad valorem tax, budget cap, taxpayer protection, spending restraint, inflation adjustment, population growth, voter approval, supermajority vote, county budget, municipal budget, school district finance, junior college district, hospital district, special district, attorney general enforcement, local fiscal limits

Transcript Highlights:

• Compounding is an essential tool for veterinarians.
• Think of mixing two or more solutions in an IV bag versus batch compounds formulated by the compounder
• Secondly, issue number 23, as it relates to compounding regulations.
• We’re not aware of any issues related to this type of compounding.
• We're not aware of any issues related to this type of compounding.

Summary: The joint Assembly and Senate business committees held a sunset review hearing on the California State Board of Pharmacy, with board leadership describing the board’s consumer-protection role and its priorities around access, enforcement, and updating pharmacy law. The board emphasized a proposed shift toward a standard-of-care model for pharmacists, arguing it would reduce rigid protocol requirements and improve access to services such as HIV PrEP/PEP, contraception, and naloxone. Board representatives also discussed pharmacy deserts, possible fee waivers for pharmacies in underserved areas, concerns about payer practices contributing to closures, continuing education audits, and a request to restore more flexibility in licensure decisions and probationary monitoring for applicants with certain criminal histories. A major focus of the hearing was the board’s ongoing compounding regulations, especially the treatment of sterile versus nonsterile compounding and substances such as glutathione and methylcobalamin. The board said the proposal was not a ban on those substances and described the rulemaking as grounded in federal law, USP standards, and public comment, noting the process had gone through multiple modified texts and hearings. Testimony from stakeholders was sharply divided: pharmacists, veterinarians, firefighters, naturopathic doctors, and patient advocates warned the rules were restricting access to compounded medications and harming patients and first responders, while the California Medical Association, psychiatric physicians, and PhRMA raised concerns that the board’s proposals could expand pharmacist authority beyond training, affect physician practice, or create safety risks. Other public comments addressed pharmacy technician ratios, remote processing, flavoring medications, hospital-specific regulation, budget and enforcement transparency, and whether the board should add members with community compounding or pharmacy technician expertise. Committee members also asked about the board’s oversight priorities and the rationale for its standard-of-care proposal. Board staff explained that consumer protection includes education, licensing, policy, and enforcement, with the highest-priority enforcement cases being those posing imminent public harm. After public testimony concluded, the chairs thanked participants and adjourned the sunset review hearing, announcing an immediate transition to the joint informational hearing on the Department of Cannabis Control.

Transcript Highlights:

• You might ask why this specific compound?
• We cannot responsibly explore the full therapeutic potential of this compound.
• There are no pharmaceutical companies out there spending a lot of money on this.
• Most people would rather take a natural medicine than a pharmaceutical product.
• Yeah, the pharmaceutical product. Well, it's anticipated.

Keywords: 959, house, all

Transcript Highlights:

• That's sort of the bottom line takeaway. the drug that was compounded under the drug that was compounded
• your children or yourself, where there has to be some specialty compounding.
• I am not in favor of GLP1s being compounded either by a 503A or a 503B.
• </c><01:11:18.719><c> and</c><01:11:18.960><c> they're</c> compound these drugs. and they're compound
• </c><01:12:00.960><c> something</c> local pharmacist can compound something local pharmacist can compound

Keywords: Public Health and Welfare - Room 216, 3 February, 2026; 3:00 PM, 925, all

Transcript Highlights:

• </c><00:27:30.880><c> uh</c> entities that manufacture compounds uh entities that manufacture compounds
• prescription drug means a drug that is compounded in a 503A facility, FDA-approved compounding facility
• prescription drug means a drug that is compounded in a 503A facility, FDA-approved compounding facility
• prescription drug means a drug that is compounded in a 503A facility, FDA-approved compounding facility
• </c> restrict access to the pharmaceutical restrict access to the pharmaceutical um<00:54:15.839><c>

Keywords: 912, senate, all

Summary: The joint HHS and LBT meeting opened with accessibility concerns, as several blind attendees arrived after the general public had already been seated. The chair apologized and said future hearings would try to seat blind members earlier. The committee also announced the hearing was being streamed on YouTube, testimony would be limited to one minute, and written testimony was available online. The first bill heard was SB 2281, relating to the use of artificial intelligence in healthcare. The Department of Health supported transparency for patients but preferred disclosure through provider websites and office signage rather than a new regulatory program. The Hawaii Medical Association and Healthcare Association of Hawaii generally supported the bill’s intent but raised concerns about administrative burden and suggested a working group or model policies. Hawaii Pacific Health said it already uses AI for note-taking and patient portal functions and worried that written notice requirements could create too much consumer information. In response, the chair emphasized that patients should be informed when AI is used, especially if it affects diagnosis or consequential decisions, and said AI should not be making medical decisions. The committee later voted to recommend SB 2281 pass with amendments, including narrowing the definition of consequential decisions, removing certain language requested by DOH, adding a two-year implementation period, and setting a far-future defective date for further discussion; both committees adopted the recommendation, with the chair voting aye and the vice chair voting with reservations. The second major bill was SB 2852, a civil rights measure focused on digital access for people with disabilities. The Hawaii State Council on Developmental Disabilities, Hawaii Civil Rights Commission, Hawaii Disability Rights Center, and the National Federation of the Blind of Hawaii all supported the bill, arguing that existing law clearly protects physical access but should also make digital access explicit. Blind testifiers described how accessible technology, such as VoiceOver on iPhones, allows them to participate independently in public processes and warned that inaccessible digital systems can create barriers for thousands of blind residents. One testifier, an attorney with disability-law experience, supported the bill’s intent but said the draft had flaws, including no exceptions for archived materials, no distinction between small and large businesses, and concerns about the timing and choice of accessibility standards; he suggested delegating regulatory authority to the Hawaii Civil Rights Commission. The bill’s sponsor said he supported DAB’s proposed amendments, and the committee indicated those amendments would address many of the concerns raised. No final vote on SB 2852 was taken in the portion provided. The committee then took up SB 2751, which defines compounded prescription drugs for workers’ compensation purposes. The Department of Labor and Industrial Relations supported the bill but requested clarifying amendments to keep pharmacists as the primary professionals authorized to compound in licensed pharmacies and to limit any physician compounding authority to the physician’s own patient. Supporters included the Work Injury Medical Association of Hawaii, while Solera Integrated Medical Solutions opposed the measure, arguing the current definition was already broad enough and warning about cost inflation, especially with 503B bulk compounding facilities and physician dispensing. In questioning, members asked about rural access, reimbursement for 503B products, and late testimony suggesting definitions for 503A and 503B facilities, limits on physician dispensing to 30 days post-injury, and pre-approval for non-FDA-approved drugs. DLIR said not every rural community has licensed pharmacists available, that products with a national drug code are reimbursed at 140%, and that 503B facilities raise concerns because they are bulk manufacturers rather than patient-specific compounding operations. The meeting then moved into decision-making on SB 2281; the chair’s pass-with-amendments recommendation was adopted by both committees, with the vice chair voting with reservations.

Transcript Highlights:

• And when it comes to pharmaceutical training, we're trained in botanical-pharmaceutical interaction.
• We are trained in botanical-pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• And when it comes to pharmaceutical training, we're trained in botanical, pharmaceutical interaction.
• training were trained in botanical, pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• pharmaceutical pharmaceutical interactions.

Bills: HB946, HB1093, SB26, SB29, SB30, SB195, SB219, SB222, SB255, SB314, SCR2, SCR22

Keywords: healthcare transparency, hospital pricing, consumer protection, collection actions, fines, naturopathic medicine, Louisiana Board of Naturopathic Medicine, licensing, healthcare, prescriptive authority, natural therapies, opioid treatment, regulation, addiction recovery, state law, SB 29, Act 732, coroner, autopsy, child death

Transcript Highlights:

• And when it comes to pharmaceutical training, we're trained in botanical-pharmaceutical interactions,
• nutraceutical interactions, and pharmaceutical interactions.
• And when it comes to pharmaceutical training, we're trained in botanical, pharmaceutical interaction.
• training were trained in botanical, pharmaceutical interactions, nutraceutical interactions, and pharmaceutical
• pharmaceutical pharmaceutical interactions.

Summary: The committee first heard and favorably reported SB 255, which expands eligibility for psychosocial rehabilitation services by adding health sciences and therapeutic recreation degrees to the list of acceptable educational backgrounds. Supporters said the change would help address workforce shortages and improve access in rural areas. SB 314 was then reported favorably; it cleans up prior law so a limited scope certified social worker license can still be used for community psychiatric support and treatment services even if the application is filed after the CSW license has expired, rather than being barred by a timing restriction. The committee next took up several bills by Chairman McMath. SB 26, which repeals facility need review requirements for opioid treatment programs, was reported favorably after members and witnesses said Louisiana has too few OTPs and that removing the review would improve access, especially in rural areas. SB 29, requiring review and reporting of a child’s immunization records in certain unexpected death autopsies, was reported favorably despite questions about whether the bill should refer more broadly to medical records; supporters said the data could help evaluate vaccine-related concerns, while opponents raised concerns about singling out immunizations. SB 30, dealing with telehealth for obesity/weight management, was amended and reported favorably; the committee adopted technical amendments and a conceptual amendment replacing “metabolic condition” with “weight management services,” while witnesses debated patient safety, board authority, and whether the bill should limit agencies’ ability to restrict telehealth in the future. The committee also reported favorably SB 219, which creates an Office of Health and Nutrition within LDH. Supporters from the department, the Alzheimer’s Association, and Pennington Biomedical said the office would strengthen coordination on nutrition, physical activity, and brain health, and cited high Alzheimer’s costs and prevalence in Louisiana. SB 222, which streamlines Medicaid behavioral health administrative requirements and expands telehealth for psychosocial rehabilitation, was reported favorably with amendments after supporters described workforce and rural access barriers. SB 195, the “Danny’s Dose EMS Treatment Act,” was reported favorably; it would allow EMS personnel to administer a patient’s own prescribed time-critical medication in emergencies, and testimony from a parent and physician described life-threatening delays under current practice. The committee also adopted SCR 2, updating hospital architectural standards to the most recent Facility Guidelines Institute edition, and SCR 22, requesting a more detailed legislative auditor report on opioid settlement expenditures; members said they wanted clearer outcome data and planned to refine the language before floor debate. Finally, HB 1093 on naturopathic medicine was introduced and heavily amended, with the bill shifted under LSBME oversight and a large set of changes discussed, but no final action was taken in the portion provided.

Transcript Highlights:

• Off of the pharmaceutical cocktail, and that's the greater harm is the pharmaceutical cocktail and the
• This compound is an anticonvulsant.
• And pharmaceutical distribution.
• Opioids and harmful pharmaceuticals.
• All these compounds work well in our system.

Bills: HB5

Keywords: hemp, cannabinoids, regulation, occupational licenses, consumable products, marketing, criminal offenses, labeling requirements, health and safety, 997, house, all

Transcript Highlights:

• However, it's like all typical pharmaceuticals: it's one single compound isolated of just CBD.
• This compound is an anti-convulsant.
• industry, producing Schedule I compounds like THC for clinical research and pharmaceuticals.
• THC is a fat-soluble compound. THC is a fat-soluble compound that means it absorbs into fat.
• CBN is a compound.

Summary: The House Committee on Public Health heard House Bill 5, a proposal to ban THC products outside the Texas Compassionate Use Program while allowing non-intoxicating CBD and CBG products under tighter regulation. Chair Van Deaver gave a lengthy background on the 2018 federal Farm Bill and Texas’s 2019 hemp law, arguing that the lack of guardrails allowed a large, unregulated THC market to develop. HB 5 would impose licensing fees, product registration, testing and inspection requirements, and restrictions intended to keep products away from children. Invited witnesses from law enforcement strongly supported the bill. Steve Dye of the Texas Police Chiefs Association and Brian Hawthorne of the Sheriffs’ Association of Texas argued that THC consumables are widely mislabeled, often far more potent than advertised, and linked to youth access, impaired driving, and organized crime. Both said regulation would be ineffective and would amount to legalization, while a ban would be easier for officers to enforce. They also emphasized support for the Texas Compassionate Use Program and said medical THC should remain available. Dr. Peter Stout of the Texas Association of Crime Lab Directors and Alice Amelot of Texas DPS testified as resource witnesses about forensic testing. They said current lab resources are already stretched thin, that quantitative testing for THC and related cannabinoids is expensive and time-consuming, and that a ban would simplify enforcement because labs could focus on presence/absence testing rather than concentration. Amelot said DPS labs are neutral on the bill but explained that mislabeled products and inaccurate certificates of analysis are common. Committee members asked about traffic safety, impairment, youth use, and the costs of enforcement and lab testing; witnesses repeatedly said the bill would reduce complexity for law enforcement but that any approach would still require more resources for labs.

Transcript Highlights:

• You can synthesize these compounds, like extracting the compound straight from a pure form.
• Compound. Does that make sense? Yes, that's for the synthetic compound.
• So, yes, these compounds exist.
• Without the need for pharmaceuticals.
• He is 100% pharmaceutical-free.

Bills: HB28, SB3, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program